1. Comparative efficacy of modified-live and inactivated vaccines in boosting responses to bovine respiratory syncytial virus, bovine parainfluenza virus Type 3, and bovine coronavirus following neonatal mucosal priming of beef calves.
- Author
-
Erickson N, Waldner C, Snyder E, Araya MB, Sniatynski M, and Ellis J
- Subjects
- Animals, Cattle, Female, Coronavirus Infections veterinary, Coronavirus Infections prevention & control, Coronavirus Infections immunology, Coronavirus Infections virology, Antibodies, Viral blood, Vaccines, Attenuated immunology, Vaccines, Attenuated administration & dosage, Respirovirus Infections veterinary, Respirovirus Infections prevention & control, Respirovirus Infections immunology, Immunization, Secondary veterinary, Coronavirus, Bovine immunology, Parainfluenza Virus 3, Bovine immunology, Respiratory Syncytial Virus, Bovine immunology, Cattle Diseases prevention & control, Cattle Diseases virology, Cattle Diseases immunology, Vaccines, Inactivated immunology, Vaccines, Inactivated administration & dosage, Respiratory Syncytial Virus Infections veterinary, Respiratory Syncytial Virus Infections prevention & control, Respiratory Syncytial Virus Infections immunology, Viral Vaccines immunology, Viral Vaccines administration & dosage, Animals, Newborn immunology
- Abstract
Objective: This study compared clinical and immunological responses to coinfection challenge of beef calves mucosally primed and differentially boosted with commercial combination vaccines containing antigens against bovine coronavirus (BCoV), bovine parainfluenza virus Type 3 (BPIV3), and bovine respiratory syncytial virus (BRSV)., Animals: Nineteen commercial beef heifers., Procedure: At birth, calves were mucosally (IN) primed with modified-live virus (MLV) vaccines, differentially boosted by injection of either combination MLV (IN-MLV) or inactivated virus (IN-KV) vaccines at a mean age of 44 d, and then challenged by coinfection with BCoV, BPIV3, and BRSV at weaning., Results: Both groups were similarly protected from clinical disease and had anamnestic neutralizing antibody responses to all 3 viruses. The IN-KV group shed more BCoV, and less BPIV3 and BRSV, than the IN-MLV group., Conclusion: These data indicated similar clinical and immunological protection between IN-MLV and IN-KV; however, shed of virus varied., Clinical Relevance: Whereas boosting with KV or MLV appeared to have similar efficacy, viral shed differences may affect disease control., (Copyright and/or publishing rights held by the Canadian Veterinary Medical Association.)
- Published
- 2024